A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer

• Status: Completed
• Trial end date: 1969-12-31

Summary

The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment

• Phase: Phase 1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Nintedanib; Paclitaxel